Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

Part of paid clinical trials in Redwood City, California.

Sponsor
Anne Chang
Study ID
NCT03079531
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Papulopustular Rosacea

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — DRUG
    Secukinumab 300 mg administered subcutaneously.

Study Details

This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.

Key Dates

Start date
Jun 21, 2017
Status verified
Jan 2020
Primary completion
Jan 25, 2019
Completion
Jan 25, 2019

Study Design

Enrollment
24 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Secukinumab arm
    Participants receive secukinumab (7 doses over a 16-week study period).

Primary Outcome Measure

Change From Baseline in Papule/Pustule Count at Week 16 [ Time Frame: Baseline, week 16 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford DermatologyRedwood CityCalifornia94603-

Find similar trials in Redwood City, CA

By research site
Stanford Dermatology· Redwood City, CA

Related Studies